[PDF] Top 20 Tema 1 Evolución Histórica del Trabajo Social

... in RECOURSE who experienced these AEs had a longer treatment duration than the overall population, and the duration of these AEs was generally a lower proportion of the total treat- ment duration in patients ... See full document

... the RECOURSE trial (n=798 patients) was partitioned into three discrete health states: toxicity (TOX), time without symptoms or toxicity (TWIST) and relapse ...affect quality of life (QoL) ... See full document

... FOLFOX4 were evaluated in the PRIME study, 8 9 in which panitumumab signi fi cantly improved overall sur- vival (OS 26.0 months) versus FOLFOX4 alone (20.2 months; p=.04) in patients with mCRC WT for KRAS and NRAS exons 2 ... See full document

... of Cancer; FAS: full analysis set; FLT3: FMS‑like tyrosine kinase‑3 receptor; HR: hazard ratio; IQR: interquartile range; IRB: institutional review board; LDH: lactate dehydrogenase; mCRC: metastatic ... See full document

... and RECOURSE trials, and Spanish real- world data includes also a subset of patients with ECOG >1, suggesting thereby that this subset of patients is not represented in clinical ...clinical trial data ... See full document

... patients’ overall quality of life (QOL). It was proven that the QOL of ESRD patients is very poor and they have to undergo lifelong treatment for their survival. QOL is used to evaluate the general well ... See full document

... the variance. The first factor was composed of all the items in the chelation therapy with a pump factor of the first EFA (q51, q6, q8, q7, and q15). The second factor was composed of four items from the disease ... See full document

... colon cancer and specific drugs have been introduced into patient ...of colorectal cancer cells and preclinical data demonstrated its central role in tumor-specific functions such as proliferation, ... See full document

... A significant limitation of the study is the small number of patients included, which resulted from considerable dif- ficulties in recruiting patients, due to, among other factors, excluding patients due to their severe ... See full document

... progression and a 34% reduction of the risk of death (p < 0.001), would have found a wide space in the oncologic practice, considering also its satisfactory toxicity profile. However, such exciting results produced by ... See full document

... Completion rates have been proposed as a quality metric because it is reasonable to assume that the effectiveness of colonoscopy is limited if the entire colon is not routinely examined. Cecal intubation is ... See full document

... Notes: Cyclin D1 activated CDK4 and then the resultant complex phosphorylates retinoblastoma protein. G1/S transition depends on the release of E2F family of transcription factors after RB is phosphorylated (P). ... See full document

... an acceptable safety profile, similar to that of other MKIs in this drug class. The recommended dose of regorafenib for future studies was determined to be 160 mg for 21 days, fol- lowed by 7 days off treatment (in ... See full document

... Markers demonstrating bevacizumab activity are lacking. Potential biomarkers to predict response to therapy have been explored. Response to therapy has not been associated with mutations in k-ras, b-raf, or p-53 (Ince et ... See full document

... [38]. Colorectal cancer represents a model for investigating the effects of angiogenesis throughout tumor ...of metastatic disease [40, ...this cancer to growth and survive, and thus to ... See full document

... IV colorectal cancer, had experienced at least one disease progression after diagnosis with mCRC, and received second-line treatment with a qualifying ... See full document

... 21. Borji M, Tavan H, Azami M, Otaghi M. The Effect of Continuous Care Model on Blood Pressure and Quality of Life in Patients on Hemodialysis. Biomedical and Pharmacology Journal; 9(2):689-95 (2016). 22. ... See full document

... Eight hundred and twenty patients with mCRC, who had progressed within 3 months of discontinuing first-line treatment with a bevacizumab-containing chemotherapy regimen, were randomized to second-line chemotherapy with ... See full document

... For the KRAS analyses, we used the commer- cially available DxS TheraScreen KRAS Mutation Kit (Qiagen, Copenhagen, Denmark). This is the standard method used in our department for routine diagnostic KRAS-mutation ... See full document

... for cancer survivors, but there is a need for better integration of lifestyle change into stand- ard models of post-cancer-treatment care ...for cancer recurrence and patients’ adoption of preventive ... See full document